Dr. Leigh Baxt, a translational scientist who works in drug development, joins Dr. Spencer Nadolsky and Dr. Karl Nadolsky to explain what actually happened with the six peptides everyone is posting about. Spoiler: they weren't approved, they weren't added to the compounding list, and the human safety data still doesn't exist.

Amanda Thebe returns to talk about how the menopause conversation went from missing to manipulated, and why she's one of the few voices saying hormone therapy doesn't work for everyone. She shares her own story, including the time a prominent menopause expert told her to get an elective hysterectomy so she could stay on estrogen.

Dr. Ken Custer, President of Lilly's Cardiometabolic Health, joins Dr. Spencer Nadolsky and Dr. Karl Nadolsky for the first big pharma executive interview in Docs Who Lift history. He breaks down the new retatrutide and eluralintide data out of EASD, why Lilly bet on a selective amylin agonist, what drug development actually costs, and where pricing and access are headed.

Obesity researchers Dr. David Allison and Dr. Emily Dhurandhar explain how they defined and built a validated questionnaire for food noise, the persistent and distressing thoughts about food that many patients say disappear on GLP-1 medications. They break down how food noise differs from hunger and cravings, where the research is going next, and why the term came from patients, not pharmaceutical companies. A quick check: the transcript never states the questionnaire's official name, so I kept it generic. If it has a published title or acronym, dropping it into the description would help with search.

Dr. Christian Rodriguez unpacks his review on metabolically healthy obesity, showing why the concept is mostly a temporary phase rather than a stable protective state. He and the hosts compare the new Lancet Commission obesity criteria against the ACE staging system, then debate GLP-1 stigma and the ethics of treating obesity before it turns severe.

Is severe, insatiable hunger a failure of willpower or hardcoded into your biology? In this episode of Docs Who Lift, Dr. Spencer and Dr. Karl Nadolsky speak with obesity specialist Dr. Jesse Richards to uncover Bardet-Biedl Syndrome (BBS), the updated 2024 diagnostic criteria, and how targeted therapies offer hope when standard GLP-1s and willpower aren't enough.

Dr. Spencer Nadolsky and Karl sit down with Dr. Susan Brian to break down one of the most significant proposed changes in women's health in decades, the potential renaming and reclassification of polycystic ovarian syndrome to anovulatory androgen excess, and what that shift means for the millions of women who have been diagnosed, misdiagnosed, or dismissed under the current framework.

Dr. Spencer Nadolsky and Karl bring on Dr. Austin Baraki and Dr. Jordan Feigenbaum from Barbell Medicine to cut through the peptide hype and explain why most of the research peptides people are currently injecting have no randomized controlled trial data in humans, were abandoned by pharmaceutical companies because they failed or showed harm signals, and may not even contain what is on the label. The core message is simple: calling something a short chain amino acids does not make it safe, natural does not mean studied, and having a standard of evidence before putting something in your body is not being close minded it is basic medicine.

Dr. Spencer Nadolsky and Karl sit down with David W, a nurse practitioner who was actually enrolled in the Triumph 1 retatrutide phase 3 trial, to break down data just presented at the American Diabetes Association conference showing average weight loss of up to 30 percent and cardiometabolic benefits that go well beyond anything tirzepatide or semaglutide produce on their own. David went from 240 pounds to 167 in the trial and walks through exactly what the experience felt like from the inside while Spencer and Karl explain what the numbers mean for patients and clinicians waiting for this drug to reach the market.

2:26 PMClaude responded: Dr.Dr. Spencer Nadolsky and Karl break down two brand new randomized controlled trials, Surmount-Maintain and Attain-Maintain, that put hard numbers on what actually happens to patients when they try to lower their tirzepatide dose, switch to oral orforglipron, or come off GLP-1 medicines entirely after significant weight loss. The data confirms what they have been seeing clinically for years: obesity biology fights hard to pull weight back up, only about 17 percent of people can come off these medicines and maintain their results, and for most patients the conversation is not about stopping but about finding the most effective and affordable long-term dosing strategy.